Tesofensine vs Livagen
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
TesofensineAnti-Aging & Longevity
Livagen- Summary
- Tesofensine is a triple monoamine reuptake inhibitor (TMRI) that blocks reuptake of serotonin, dopamine, and norepinephrine. Originally developed for Alzheimer's and Parkinson's disease, it was repurposed as a potent weight loss agent after clinical trials demonstrated substantial fat loss via appetite suppression and increased energy expenditure.
- Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
- Half-Life
- 8-10 days (exceptionally long; accumulates over weeks)
- Short (minutes); gene-regulatory effects are sustained
- Admin Route
- Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.25-0.5 mg per day
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Potent appetite suppression via triple monoamine reuptake inhibition
- Significant weight loss (8-12% body weight in phase II trials at 0.5 mg)
- Increases basal metabolic rate and energy expenditure
- Reduces fat mass preferentially over lean mass
- Potential cognitive benefit via dopaminergic and noradrenergic enhancement
- Longer half-life than sibutramine allows once-daily dosing
- Supports hepatocyte regeneration and liver tissue repair
- Normalizes liver cell protein synthesis
- Immune modulation via thymic activity
- Potential benefits in chronic hepatitis and liver aging
- Anti-aging effects on hepatic tissue
- May support liver recovery after toxic insult or alcohol damage
- Complementary to NAD+ and glutathione in liver health protocols
- Side Effects
- Elevated heart rate and blood pressure (sympathomimetic)
- Dry mouth
- Insomnia and sleep disturbances
- Nausea
- +4 more
- Generally well tolerated
- Mild injection site reactions
- No significant hepatotoxic effects reported at standard doses
- Stacks With
- —
- —